Moreover, CHEK2.1100delC can be detected in 5.1% of the non-carriers of the BRCA1 or BRCA2 mutations with FH in northern Europe (102), and such mutation in females can increase the risk of developing BC by 2–3 times, and by 10 times in males (103, 104). This evidence concerns the gene CHEK2 and breast cancer.